Suppr超能文献

基于计算机断层扫描的图像引导近距离放疗在局部晚期宫颈癌中的剂量学可行性:一项日本前瞻性多机构研究。

Dosimetric feasibility of computed tomography-based image-guided brachytherapy in locally advanced cervical cancer: a Japanese prospective multi-institutional study.

机构信息

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.

Department of Radiology, Kaizuka city hospital, 3-10-20 Hori, Kaizuka, Osaka, 597-0015, Japan.

出版信息

J Radiat Res. 2021 May 12;62(3):502-510. doi: 10.1093/jrr/rraa138.

Abstract

The aim of this study was to assess the feasibility of planning dose-volume histogram (DVH) parameters in computed tomography-based 3D image-guided brachytherapy for locally advanced cervical cancer. In a prospective multi-institutional study, 60 patients with stage IIA2-IVA cervical cancer from eight institutions were treated with external beam radiotherapy using central shielding and intracavitary or hybrid (combined intracavitary/interstitial) brachytherapy (HBT). The dose constraints were set as a cumulative linear quadratic equivalent dose (EQD2) of at least 60 Gy for high-risk clinical target volume (HR-CTV) D90, D2cc ≤ 75 Gy for rectum, D2cc ≤ 90 Gy for bladder and D2cc ≤ 75 Gy for sigmoid. The median HR-CTV D90 was 70.0 Gy (range, 62.8-83.7 Gy) in EQD2. The median D2cc of rectum, bladder and sigmoid was 57.1 Gy (range, 39.8-72.1 Gy), 68.9 Gy (range, 46.5-84.9 Gy) and 57.2 Gy (range, 39.2-71.2 Gy) in EQD2, respectively. In 76 of 233 sessions (33%), 23 patients underwent HBT, and the median number of interstitial needles was 2 (range, 1-5). HBT for a bulky HR-CTV (≥40 cm3) significantly improved the HR-CTV D90 compared with intracavitary brachytherapy alone (P = 0.010). All patients fulfilled the dose constrains for target and at risk organs by undergoing HBT in one-third of sessions. We conclude that the planning DVH parameters used in our protocol are clinically feasible.

摘要

本研究旨在评估在基于 CT 的 3D 图像引导近距离放疗中规划剂量体积直方图 (DVH) 参数治疗局部晚期宫颈癌的可行性。在一项前瞻性多中心研究中,来自 8 个机构的 60 例 IIA2-IVA 期宫颈癌患者接受了外部束放疗,采用中央屏蔽和腔内或混合(腔内/间质联合)近距离放疗 (HBT)。剂量限制设定为高危临床靶区 (HR-CTV) D90 的累积线性二次等效剂量 (EQD2) 至少 60Gy,直肠 D2cc ≤ 75Gy,膀胱 D2cc ≤ 90Gy 和乙状结肠 D2cc ≤ 75Gy。中位 HR-CTV D90 的 EQD2 为 70.0Gy(范围,62.8-83.7Gy)。直肠、膀胱和乙状结肠的中位 D2cc 分别为 57.1Gy(范围,39.8-72.1Gy)、68.9Gy(范围,46.5-84.9Gy)和 57.2Gy(范围,39.2-71.2Gy)。在 233 次治疗中,有 76 次(33%)采用了 HBT,其中 23 例患者接受了 HBT,间质针的中位数为 2 根(范围,1-5 根)。与单纯腔内近距离放疗相比,对于大体积 HR-CTV(≥40cm3),HBT 显著提高了 HR-CTV D90(P=0.010)。通过 HBT 进行三分之一的治疗,所有患者均满足靶区和危险器官的剂量限制。我们的结论是,我们方案中使用的计划 DVH 参数在临床上是可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f611/8127675/3d9ab337735d/rraa138f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验